ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 27.98% |
2CI | CIGNA GROUP | Healthcare | $78.07B | 20.89% |
3CNC | CENTENE CORP | Healthcare | $34.79B | 9.31% |
4ZTS | ZOETIS INC | Healthcare | $33.71B | 9.02% |
5THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 6.11% |
6UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 2.99% |
7DVA | DAVITA INC | Healthcare | $10.95B | 2.93% |
8BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 2.67% |
9OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 2.65% |
10GMED | GLOBUS MEDICAL INC | Healthcare | $9.58B | 2.56% |
11EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 1.34% |
12NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 1.06% |
13OGN | ORGANON & CO | Healthcare | $3.65B | 0.98% |
14BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.83% |
15ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.79% |
16ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.67% |
17MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.66% |
18HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.53% |
19NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.46% |
20HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.45% |
21ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.43% |
22TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.42% |
23AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.39% |
24PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.39% |
25INVA | INNOVIVA INC | Healthcare | $1.35B | 0.36% |
26OMER | OMEROS CORP | Healthcare | $1.30B | 0.35% |
27AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.33% |
28VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.32% |
29NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.31% |
30IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.30% |
31RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.23% |
32VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.21% |
33ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.18% |
34TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.16% |
35CTEV | CLARITEV CORP | Healthcare | $459M | 0.12% |
36PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.11% |
37EMBC | EMBECTA CORP | Healthcare | $364M | 0.10% |
38VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.09% |
39AGEN | AGENUS INC | Healthcare | $311M | 0.08% |
40QTTB | Q32 BIO INC | Healthcare | $264M | 0.07% |
41SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.07% |
42UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.06% |
43OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.04% |
44RLYB | RALLYBIO CORP | Healthcare | $84M | 0.02% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $373.76B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 94% toward Large, 7% toward Growth. +1% unclassified (3 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 44 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 44 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 32%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 34.5% | 42.0% |
| 3 yearsp.a. | 21.4% | 11.8% |
| 5 yearsp.a. | 10.4% | 4.7% |
| 10 yearsp.a. | 10.9% | -3.3% |
| Since inceptionp.a. | 13.2% | 1.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 35.1% | 35.4% |
| 2025 | 36.8% | 33.0% |
| 2024 | -7.6% | -24.2% |
| 2023 | -17.2% | -40.8% |
| 2022 | 6.4% | 46.9% |
| 2021 | 27.1% | 4.6% |
| 2020 | 5.3% | -22.9% |
| 2019 | 19.0% | -0.4% |
| 2018 | 6.7% | -10.6% |
| 2017 | 9.9% | -16.8% |
| 2016 | -3.8% | 13.9% |
| 2015 | 12.8% | -4.7% |
| 2014 | 28.2% | 0.5% |
| 2013 | 41.3% | -11.3% |
| 2012 | 12.7% | -6.7% |
| 2011 | 23.1% | 10.5% |
| 2010 | 9.6% | 2.3% |
| 2009 | 25.9% | 1.2% |
| 2008 | -42.1% | -29.9% |
| 2007 | 7.2% | -9.9% |
| 2006 | 22.0% | 17.4% |
| 2005 | 19.2% | -10.0% |
| 2004 | 37.7% | 21.9% |
| 2003 | 46.7% | 1.0% |
| 2002 | -13.4% | 15.6% |
| 2001 | 5.4% | 18.2% |
| 2000 | 59.8% | 58.3% |
| 1999 | 12.5% | 18.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Enterprise Multiple Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Enterprise Multiple signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.